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ABSTRACT: We examined the effects of non-competitive
NMDA glutamate receptor antagonists on seizures elicited by
4-aminopyridine (4-AP), and in particular, on the expression
of the transcription factor c-fos induced by these seizures.
Induction of c-fos mRNA due to 4-AP-elicited seizures was as-
certained by reverse transcription polymerase chain reaction in
samples of the neocortex. Adult rats were pretreated with the
NMDA receptor antagonists amantadine (40mg/kg), ketamine
(3mg/kg), dizocilpine (MK-801; 1mg/kg) or dextrometorphan
(40mg/kg); 4-AP (5mg/kg) was then injected i.p. Controls were
treated with either antagonist only or with 4-AP only. Pretreat-
ment with the antagonists (with the exception of amantadine)
increased the latency of behavioural seizures, but not all of
the antagonists caused symptomatic seizure protection. In the
brains which were processed for Fos immunohistochemistry,
quantitative evaluation of immunostained cells was performed
in the neocortex and hippocampus. Treatment with either an-
tagonist did not induce by itself c-fos expression, with the
exception of amantadine, which caused slight Fos induction in
the neocortex. Pretreatment with all the antagonists resulted
in decrease of seizure-induced Fos immunoreactivity with re-
spect to non-pretreated animals. Decrease of immunostained
cells was significant in the neocortex, in the granule cell layer
and hilus of the dentate gyrus, in hippocampal areas CA1
and CA2. MK-801, ketamine and dextrometorphan decreased
significantly Fos immunoreactivity also in area CA3. The de-
crease of Fos immunostaining was not directly correlated with
a suppression of behavioural seizures. The results support an
important role of NMDA receptors in c-fos gene induction in
acute 4-AP seizures.
© 2002 Elsevier Science Inc. All rights reserved.
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INTRODUCTION
The c-fos protooncogene is an inducible transcription factor [22],
which belongs to the AP-1 family and exerts various regula-
tory actions in the cell nucleus. Very little is known about the
genes which are regulated through the action of c-fos, but the
signals and intracellular pathways which lead to expression of
the c-fos gene have been identified. In general, membrane depo-
larisation, Ca2+ influx, cAMP and some growth factors are able
to influence c-fos expression, predominantly by means of intra-
cellular protein kinase cascades. Expression of c-fos, typically
induced by epileptic seizures, is mediated mainly by transmit-
ters acting on ionotropic receptors and the voltage-dependent
Ca2+ channels in the membrane [20]. In vitro experiments
have demonstrated that the nicotinic acetylcholine receptor, and
glutamate receptors of the N-methyl-d-aspartate (NMDA) and
α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)
types, are able to activate c-fos expression [22]. In vivo, the NMDA
and AMPA receptors are the main candidates for such activation
[20]. The AP-1 regulatory proteins (Fos, Fra and Jun) participate
in the regulation of degeneration and regeneration in the develop-
ing and adult brain (details of this regulation have recently been
discovered [21]).
The compound 4-aminopyridine (4-AP) is a blocker of K+ con-
ductances, and specifically those of the IK(A) and IK(V) currents
[1]. The delay in neuronal repolarisation increases transmitter re-
lease and augments inhibitory and excitatory postsynaptic poten-
tials [45,53,57]. If injected i.p., 4-AP causes generalised seizures
[34]. Our previous studies indicated that focal and systemic ad-
ministration of 4-AP induces rapidly an intense and long-lasting
expression of c-fos in the neocortex and hippocampus [35,37].
Based on the mechanism of action of 4-AP, this effect was pre-
sumed to be mediated by transmitter actions: membrane depolar-
isation and Ca2+ influx. Literature data indicate that glutamate is
the main candidate in the precipitation and maintenance of 4-AP
seizures [18,25]. Both NMDA and non-NMDA glutamate recep-
tors are known to contribute to the in vitro ictagenic effects of 4-AP
[18]. Studies involving intracellular recording in rat neocortical
slices have shown that NMDA receptors contribute to the process
of stimulus-induced paroxysmal depolarisation shift amplification
by prolonging the duration and reducing the latency of the epilep-
tiform discharge [25].
The anticonvulsant properties of glutamate receptor an-
tagonist drugs have been reported in various in vivo and in
vitro epilepsy models [32,42,48]. The competitive and selective
NMDA antagonists 2-amino-7-phosphonoheptanoic acid (AP7)
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and 2-amino-5-phosphonovaleric acid (AP5) have been demon-
strated to be potent antiepileptic agents when given i.c.v. to mice
[12,33]. High-affinity open-channel NMDA receptor blockers such
as phencyclidine, ketamine and dizocilpine (MK-801) are also
potent anticonvulsants [3,56] and protect against seizure-related
brain damage [9,10]. Low-affinity open-channel NMDA receptor
blockers such as amantadine (1-aminoadamantane), memantine
(1-amino-3,5-dimethyladamantane), remacemide, dextrometor-
phan ((+)-3-methoxy-N-methylmorphinan) and its metabolite
dextrorphan also display anticonvulsant and neuroprotective ac-
tivities [24,41,47–49]. Some of these antagonists are already in
clinical use [6]. The aim of the present study was to test the
changes in c-fos expression in the 4-AP seizure model follow-
ing pretreatment with NMDA receptor antagonists, and thereby
estimate the contribution of NMDA receptors to the seizure
process.
MATERIALS AND METHODS
Animals and Treatment
Experiments were performed on a total of 111 male Wistar
rats weighing 180–200 g. The experiments were conducted in
accordance with prevailing laws and ethical considerations. Writ-
ten permission was obtained in advance from the Faculty Ethical
Committee on Animal Experiments (University of Szeged). The
animals had free access to food and water. The convulsant agent
4-AP (Sigma, St. Louis, MO) was dissolved in saline (0.67 mg
in 1 ml vehicle) and administered i.p. (5 mg/kg). In previous
investigations, this dose proved to be epileptogenic [34,35].
Pretreatment with ketamine (3 mg/kg), MK-801 (1 mg/kg),
amantadine (40 mg/kg) or dextrometorphan (40 mg/kg) (all pur-
chased from Sigma) was performed in four groups, each contain-
ing three animals (12 animals). The tested drugs were dissolved
in saline and injected i.p. in a volume of 1 ml, 10 min prior to the
application of 4-AP. One control group (three animals) received
the same amount of solvent (0.9% sodium chloride in distilled
water) and 4-AP (5 mg/kg). Other control groups received only
the tested drugs, without 4-AP (12 animals). Finally, an additional
control group (three animals) received only physiological saline.
All of the above animal groups were used for immunohistochem-
istry (30 rats in total). At the end of the experiment, 3 h after the
i.p. injections of 4-AP, the animals were deeply anaesthetised with
diethyl ether and perfused transcardially with 200 ml of 0.1 M
phosphate-buffered saline (PBS), pH 7.4, followed by 300 ml of
fixative (4% phosphate-buffered paraformaldehyde, pH 7.4). This
time of exposure to 4-AP is within the interval in which the Fos
protein can be identified or is maximal in the neurons that express
the c-fos gene [17,35,59].
The brains were rapidly removed, postfixed in 4% paraformalde-
hyde for 1 h, and then cryoprotected overnight (30% sucrose in
0.1 M phosphate buffer, pH 7.4) at room temperature. Serial frozen
sections were cut on a cryostat (Reichert-Jung Cryocut 1800) in
the coronal plane at a thickness of 24µm and one every third
section was then processed for immunohistochemisty.
The behavioural outcome of the pretreatment with the antag-
onists, and in particular the latency of the onset of generalised
tonic-clonic convulsions from the time of 4-AP injection, was eval-
uated in parallel experiments, in groups of 15 animals each (75
animals; Table 1).
c-fos mRNA Detection
Six rats were used in this part of the study: three animals were
decapitated 1 h following saline injection, and three additional rats
were sacrificed 1 h following administration of 4-AP (5 mg/kg);
TABLE 1
BEHAVIOURAL ANALYSIS OF THE EFFECT OF NMDA ANTAGONISTS ON
4-AP SEIZURES
Animals
GTCS Latency Displaying
Compound/s (min) SEM GTCS (%)
4-AP 30.3 1.4 100
4-AP + amantadine 26.2 2.0 100
4-AP + dextrometorphan 45.0* 4.3 83.3
4-AP + ketamine 45.3* 4.7 61.1
4-AP + MK-801 34.2 4.5 27.7
The tests were conducted in groups of 15 animals each. The antagonists
were injected i.p. Ten minutes later, 4-AP was administered, and the
latencies of the onset of GTCS were measured from the time of the
4-AP injection. Significant differences are indicated. Abbreviations: GTS,
generalised tonic-clonic seizures; SEM, standard error of the mean.
∗ p < 0.05; ANOVA followed by the post hoc Bonferroni test.
the latter group displayed behavioural seizures. Under anaesthe-
sia with diethyl ether, the rats were decapitated, the brains were
quickly dissected and samples of the parietal cortex were frozen
in liquid nitrogen. Tissue samples were homogenised and the to-
tal RNA was extracted by the AGPC method [8]. The reverse
transcription (RT) was made from 2µg RNA as in [60]. One mi-
crolitre of the 20µl RT product was submitted to multiplex poly-
merase chain reaction (PCR) in 50µl volume of Taq reaction
buffer containing 0.25µM glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) primers, 2.5µM c-fos primers, 200µM dNTP,
1.5 mM MgCl2 and 1 unit of Taq DNA polymerase. The sequence
of GAPDH primers [60] and the sequence of c-fos primers [4]
have been described. Amplification was carried out in 25 cycles
after carefully establishing the linearity for both the GAPDH and
c-fos fragments between 20 and 30 cycles. Identity of the c-fos
PCR fragment (256 bp) and the GAPDH fragment (377 bp) was
confirmed by cloning into pGEM-T easy vector and sequencing.
All chemicals were purchased from Sigma. The RT–PCR products
were separated on 6% acrylamide gel and stained with ethidium
bromide. Quantification of the bands was performed by densito-
metric scanning, using the ScanPack 10.1 A20 program (Biometra,
Göttingen, Germany). The paired Student’s t-test was used for sta-
tistical analysis. The levels of c-fos transcript in each of the sam-
ples were normalised to the level of GAPDH mRNA detected from
the same amplification reaction.
Immunohistochemistry
Polyclonal c-fos antibody (raised in rabbit; Santa Cruz Biotech-
nology, CA) and the peroxidase–antiperoxidase (PAP) method
were used. The sections were pretreated with 1.5% H2O2 and
rinsed in 0.1 M PBS containing 0.2% Triton X-100. They were
then incubated in 20% normal pig serum, next in primary c-fos
antibody (1:1000 in 20% normal pig serum in PBS and 0.2%
sodium azide), and then in donkey anti-rabbit IgG (1:40; Jackson
Immuno-Research, PA). The secondary antibody was detected by
the PAP technique (PAP complex diluted to 1:1000). The per-
oxidase reaction was localised with nickel chloride-containing
diaminobenzidine tetrahydrochloride (Sigma), yielding a black
reaction product.
Analysis of the Immunohistochemical Data
Quantitative analysis was performed on five sections per
animal, selected from every brain on the basis of the same stereo-
taxic coordinates [43]. Areas of interest (AOIs) for counts of
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immunostained neuronal nuclei were selected from the S1Tr re-
gion of the neocortex [43], regions CA1, CA2 and CA3 of the
Ammon’s horn, and from the hilus and granule cell layer of the
dentate gyrus [43].
Within each AOI, the immunoreactive cell nuclei were counted
using a Nikon Eclipse 600 microscope equipped with a SPOT
RT Slider digital camera (1600 × 1200 dpi in 8 bits), using the
Image Pro Plus 4 morphometry software (Media Cybernetics,
Silver Spring, MD). Following background subtraction, the thresh-
old was determined so that all labelled nuclei could be recognised.
The counting was performed blindly of the animal’s treatment.
The AOIs were determined using the rectangular field of the
camera.
In the neocortex, cell counts were done using a 10× objective,
and the AOI (an area of 1.2 mm2) included all neocortical layers
(I–VI) from the pia mater to the subcortical white matter (see
Fig. 2), so that the layers were not evaluated separately. Cell counts
were then normalised to 1 mm2. In the hippocampus, cell counts
were done using a 40× objective, and were again normalised to
1 mm2. In regions CA1–3, the AOI (an area of 0.05 mm2) included
the stratum pyramidale and a narrow zone of the strata oriens and
radiatum. The hilus of the dentate gyrus was outlined according
to Amaral [2], and counting was performed. The whole extent of
the upper and lower blades of the granule cell layer was outlined
and used as AOI, and labelled cell nuclei were counted in this
area. The molecular layer of the dentate fascia contained very few
Fos-labelled nuclei and was not evaluated quantitatively.
The data were analysed statistically comparing sets of findings
obtained with the same magnification. Differences in the number of
Fos-positive cells in the control and the different drug-treated ani-
mals were analysed with one-way analysis of variance (ANOVA),
followed by the Bonferroni post hoc test. A significance criterion
of 0.05 was used. The statistical analysis was performed with the
SPSS 9.0 software.
FIG. 1. Level of c-fos mRNA in the cerebral neocortex following 4-AP seizures (S, stim-
ulated) and controls (C, control). The columns are the means from three experiments, the
vertical bars indicating the standard error of the mean (SEM). The difference is significant
(∗p < 0.05). The inset shows the representative gel of the multiple amplification.
RESULTS
Behavioural Analysis
As stated above, groups of animals were destined only to the
observation of the behavioural effects of the treatments (Table 1).
The i.p. administration of 4-AP caused characteristic behavioural
symptoms within 15 min: first, tremor of the vibrissal and mas-
ticatory muscles, followed by generalised tremor of the body
musculature, detectable as continuous fasciculation of the mus-
cles, and generalised tonic-clonic seizures (GTCS). The symp-
toms of the GTCS were always sudden and clear-cut, and we
could, therefore, easily measure the latency of the GTCS onset
(Table 1). Such latency increased significantly in the animals
pretreated with ketamine and dextrometorphan, whereas amanta-
dine and MK-801 did not cause any significant change. However,
MK-801 pretreatment prevented the development of GTCS in
72.3% of the animals (Table 1). Ketamine exerted a similar,
although less pronounced effect: 38.9% of the animals were
protected from GTCS. The least effective in this respect was
dextrometorphan: only 16.7% of the rats were protected from
GTCS (Table 1). Amantadine did not influence instead the seizure
symptoms (Table 1). The symptoms preceding GTCS (tremor of
the vibrissae, tremor of the masticatory muscles and generalised
tremor) were similar in all groups, except for that of the animals
pretreated with MK-801. In the latter rats, instead of tremor, the
first symptoms were hypotonia of the limbs and unsteady gait, after
which generalised tremor also developed. The main behavioural
symptoms disappeared after 90–120 min at the latest; the animals
then displayed mild tremor or brief myoclonic episodes. By the
end of the experiment (3 h), all animals recovered completely.
Antagonists given alone did not cause any obvious behavioural
change.
The animals used for the immunohistochemistry experiments
displayed different seizure symptoms according to the treatment.
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Thus, all of these rats showed generalised tremor, but GTCS
developed only in the animals pretreated with amantadine or
dextrometorphan. In the ketamine-pretreated group, two animals
developed GTCS 60 and 75 min following treatment. None of the
MK-801-treated animals displayed GTCS.
Expression of c-fos mRNA
The message of c-fos was detectable in the brains of control
and 4-AP-treated rats, as was the internal control GAPDH mRNA
(Fig. 1). In the control (saline-treated) and in the 4-AP-treated rats,
the GAPDH message was not different; however, 4-AP treatment
increased the level of c-fos mRNA highly significantly, from 117±
28 arbitrary units (saline-treated) to 602± 74 units (4-AP-treated)
(Fig. 1).
Immunohistochemistry
Fos-positive cell nuclei were detected in every layer of the
neocortex and in the hippocampus 3 h following 4-AP administra-
tion. In the neocortex, a large number of Fos-positive cells were
distributed in layers II–VI (Fig. 2A). Pretreatment with 40 mg/kg
FIG. 2. Low-magnification images of the distribution of Fos-positive cell nuclei in the neocortex 3 h following 4-AP injection. (A)
treated only with 4-AP; (B) amantadine pretreatment; (C) dextrometorphan pretreatment; (D) ketamine pretreatment; (E) MK-801
pretreatment; (F) treated only with ketamine (layers are indicated by roman numerals). Bar: 250µm.
amantadine, 40 mg/kg dextrometorphan, 3 mg/kg ketamine, or
1 mg/kg MK-801 prior to administration of the convulsant agent
resulted in a significantly lower number of Fos-immunoreactive
nuclei with respect to the non-pretreated animals. Regarding the
distribution of labelled cell nuclei, amantadine caused an overall
decrease, but strongly stained nuclei were still observed in layers
II, III and V (Fig. 2B). Dextrometorphan pretreatment resulted in
marked decrease of labelled cells in layers II, III, IV and VI, but
a less marked decrease in layer V (Fig. 2C). Ketamine suppressed
Fos-like immunostaining in most of the cortical layers, but not in
layer IV, which contained numerous Fos-labelled cells (Fig. 2D).
MK-801 caused an overall decrease of Fos immunoreactivity, with
a staining pattern similar to that observed after dextrometorphan
pretreatment (Fig. 2E).
Quantitation revealed that the number of Fos-containing cell nu-
clei was consistently and significantly lower in animals pretreated
with either NMDA antagonist drug than in those treated with 4-AP
only (Fig. 4A). It should be reminded, in this respect, that these
data were collected across the thickness of the neocortex and not
in individual layers (see Fig. 2A–F).
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Regions CA1–3 of the hippocampus displayed strong Fos-like
staining, mainly in the pyramidal layer. A few scattered nuclei were
stained in the strata oriens, radiatum and lacunosum-moleculare.
The neurons of the dentate gyrus displayed strong staining, whilst
the hilar region contained strongly stained, scattered cell nu-
clei (Fig. 3A). Pretreatment with amantadine, dextrometorphan,
ketamine or MK-801 resulted in a significantly lower number
of Fos-labelled neurons in CA1, CA2 and CA3 regions of the
FIG. 3. Low magnification images of the distribution of Fos-positive cell nuclei in the hippocampus. The sectors of Ammon’s horn
(CA1, CA2 and CA3) are indicated. Arrow points to the granule cell layer of the dentate fascia, while the asterisk shows the hilus of
the dentate fascia. (A) treated only with 4-AP; (B) effect of amantadine; (C) effect of dextrometorphan; (D) effect of ketamine; (E)
effect of MK-801; (F) treated only with MK-801. The arrowhead in (F) indicates c-fos staining in the dorsal thalamus. Bar: 500µm.
Ammon’s horn with respect to the animals that had received
4-AP only (Figs. 3B–E and 4C). The less effective among the
antagonists was amantadine, which, however, resulted in signif-
icant changes in all the above regions, except for CA3 (Fig. 4).
Pretreatment with amantadine, MK-801, ketamine or dextrome-
torphan reduced Fos immunoreactivity in the dentate granule cell
layer (Fig. 3B–E), as confirmed by statistical evaluation (Fig. 4B).
Moreover, amantadine, ketamine, dextrometorphan and MK-801
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FIG. 4. Quantitative evaluation of Fos-positive cells in the different experimental groups. (A) results of cell counts in
the neocortex in amantadine-, dextrometorphan-, ketamine- or MK-801-pretreated animals, compared with rats injected
only with 4-AP. The results of cell counts in the neocortex of rats injected only with NMDA antagonists are shown in
the “controls” panel (inset). Note that amantadine caused significant c-fos expression compared to untreated controls. The
first column on the inset diagram displays the number of Fos-stained nuclei following saline injection. Dextrometorphan,
ketamine and MK-801 did not cause any significant change. (B) results of cell counts in the granule cell layer of the
dentate gyrus in antagonist-pretreated and 4-AP-injected rats compared with animals injected only with 4-AP. (C) results
of cell counts in the hippocampus and hilus of the dentate gyrus in antagonist-pretreated and 4-AP-injected rats compared
with animals injected only with 4-AP. Asterisks denote significant differences (p < 0.001; ANOVA, post hoc Bonferroni
test); SEM is indicated in every case; IR, immunoreactive.
resulted in a significant decrease of the number of Fos-containing
cell nuclei in the dentate hilus (Fig. 4C).
When given alone, the antagonists caused only minimal cor-
tical Fos induction (Figs. 2F and 3F). In the neocortex, amanta-
dine and MK-801 administration resulted in the relatively highest
number of labelled cells, but only amantadine resulted in a signifi-
cant difference compared to controls injected with saline (Fig. 4A,
inset). The number of stained cells induced by MK-801, dextrome-
torphan and ketamine was consistently very low, without signif-
icant differences (Fig. 4A, inset). None of the antagonists did
induce a significant increase of Fos expression in the hippocampus
(not shown).
DISCUSSION
Previous studies from our laboratory indicated that the 4-AP
model is a reliable one for the pharmacological investigation
of seizure genesis [34], and that careful counting of the Fos
protein-immunostained cell nuclei serves as an indicator of seizure
spread in forebrain structures in vivo [35,36]. Our previous studies
proved that the Fos protein was detectable in the forebrain by
Western blotting in 4-AP seizures [37]. In the present experiments,
the RT–PCR studies demonstrated the induction of c-fos mRNA
in the cerebral cortex following 4-AP injection. This is the first
such report in the literature.
In a previous investigation [35], strong Fos immunostaining
was observed in both the neocortex and the allocortex at 3 h af-
ter 4-AP injection, and we therefore chose an interval of 3 h for
immunohistochemistry in the present study. On the basis of our
evaluation, we conclude that all the NMDA receptor antagonists
decreased significantly the seizure-induced expression of c-fos in
the neocortex and in the allocortex. However, not every antagonist
caused symptomatic seizure protection. Our experiments indicated
that only ketamine, MK-801 and dextrometorphan attenuated the
symptoms of the seizure: ketamine and dextrometorphan increased
the latency of the GTCS significantly; MK-801, ketamine and
dextrometorphan decreased the incidence of the GTCS. No pro-
tective effect was seen in the amantadine-pretreated animals. We,
therefore, believe that the immunohistochemical results reflect the
antagonistic effect of the drugs on the receptor, and can be cor-
related only indirectly with the behavioural effects shown by the
animals.
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Mechanism of Action of Non-Competitive NMDA Antagonists
Ketamine, MK-801, amantadine and dextrometorphan decrease
the postsynaptic effects of glutamate mainly by blocking the
NMDA receptor channel. The isotope-labelled derivatives of these
compounds (except for dextrometorphan) are used in human brain
imaging studies to investigate the glutamate receptor function [6].
Ketamine and MK-801 are high-affinity open-channel blockers:
they block the ion channel of the receptor at the phencyclidine site
and inhibit or decrease the ion fluxes which follow the glutamate
binding [7]. MK-801 administration, i.p. and i.c.v., was found to
protect against 4-AP seizures in electrophysiological experiments
[39]. The present experiments provided further data on the seizure
protection, and proved that pretreatments prevent GTCS and reduce
c-fos induction in the neocortex and hippocampus.
The literature data on the effects of ketamine are not univocal:
no effects were seen on the epileptiform activity induced by 4-AP
in hippocampal slices [50], but ketamine was found to be effective
against picrotoxin seizures in vitro [30] and electroconvulsions in
vivo [52]. Ketamine has been reported to be useful in the therapy
of refractory status epilepticus in humans [51]. This drug and its
isomers have a proven neuroprotective effect in different condi-
tions such as seizures [9] and ischaemia [46]. In the present exper-
iments, seizure latency data were indicative of an anticonvulsant
role of ketamine in 4-AP seizures. The decrease in c-fos expres-
sion is clearly a sign of decreased Ca2+ influx into the neuron.
These effects might be related to the NMDA receptor antagonism
of ketamine and its blocking action on Na+ channels [61].
Amantadine is a low-affinity open-channel antagonist [40];
the family of aminoadamantanes displays antiparkinsonian-like
activity as well as neuroprotective action [13]. Memantine
(1-amino-3,5-dimethyladamantane) has better therapeutic indices
than amantadine and is used in the therapy of epilepsy and other
neurological and psychiatric disorders. The present experiments
prove that amantadine decreases seizure-induced c-fos expression
in the neocortex and in the hippocampus, with the only exception
of the CA3 region. Possibly, Ca2+ fluxes are able to displace
the antagonist from the channel resulting in the cessation of its
effect. From these results, we conclude that amantadine probably
decreases transiently the Ca2+ influx through the NMDA receptor,
and this was reflected by the decrease of seizure-induced c-fos
expression. However, this drug does not provide protection against
the behavioural seizure.
The effects of dextrometorphan are more complex. This com-
pound inhibits NMDA-induced convulsions and is, therefore, re-
garded as a non-competitive antagonist [11,16]. It also diminishes
kainic acid seizures and attenuates the consequent hippocampal
neuronal damage [27]; it inhibits ischaemia-induced c-fos expres-
sion and neuronal death [5]. Some of the effects of dextrome-
torphan are mediated by the NMDA receptors, and some by the
voltage-dependent Ca2+ and Na+ channels [55]. The effects of
dextrometorphan observed in our experiments are very promising:
the decrease in Fos-protein-like immunoreactivity elicited by the
seizures in cortical layers indicated that the Ca2+ influx was sub-
stantially inhibited. Dextrometorphan also increased significantly
the latency of the GTCS.
c-fos Expression as Marker of Neuronal Activity
Our findings concerning the appearance of c-fos in the con-
vulsing brain are in accord with literature data [14,15,58]. The
appearance of synchronised population spikes was found to corre-
late well with c-fos mRNA expression, which also correlated with
presynaptic glutamate release [29]. The detection and evaluation of
Fos immunoreactivity, therefore, appears suitable for the histolog-
ical mapping of epileptic neuronal activity [29,35–37]. Literature
data [22,29] lead us to consider that 4-AP induces c-fos expression
in part through increased release of glutamate from cerebrocortical
synapses in vivo, and in part through the concomitantly increased
Ca2+ influx into the postsynaptic cell. Accordingly, decreased
seizure-induced c-fos expression following the administration of
NMDA antagonists should indicate weakening of the postsynaptic
effects of glutamate and concomitant influx of Ca2+ [20]. How-
ever, previous literature data indicated that the NMDA antagonist
MK-801 decreased c-fos induction significantly, but did not abol-
ish the hippocampal electroencephalographic seizure [29]; this
parameter was not examined in the present investigation.
The postsynaptic membranes of neocortical and hippocampal
neurons possess not only NMDA, but also AMPA and kainate re-
ceptors [31]. These ionotropic receptors respond to extracellular
glutamate: AMPA receptors trigger depolarisation and burst initi-
ation, and NMDA receptors become then activated and the open-
ing of the NMDA channel generates large Ca2+ influx [25,31].
The blockade of the NMDA channel by non-competitive antago-
nists obviously inhibits or delays the influx of Ca2+, which in turn
should delay or inhibit the long-lasting neuron depolarisation [25].
Since c-fos induction is a graded response once it reaches a min-
imal threshold for expression [29], different c-fos expression pat-
terns (resulting in a variation in the number of Fos-positive cells
and different staining intensity) are plausible.
It is, however, important to emphasise that GTCS, which rep-
resents the main symptom of the 4-AP treatment, did not show
a strict correlation with c-fos expression. Animals pretreated with
NMDA antagonists and exhibiting decreased c-fos expression dis-
played GTCS, although the latency and incidence of the symptom
were affected significantly. One explanation of this observation
may be that the induction of the c-fos gene in response to increased
release of glutamate occurs in a critical period, during which in-
crease of glutamate release and facilitation of voltage-dependent
Ca2+ channels trigger those intracellular cascades which eventually
lead to c-fos expression [20,29]. Inhibition of the NMDA receptor
channel during this period could inhibit the induction of the c-fos
gene, whereas glutamate release after this critical period may not
induce further c-fos expression, but may cause and maintain the
symptoms. This could explain the discrepancy between the occur-
rence of GTCS and the decrease of Fos immunoreactivity. Another
explanation could be based on the role of non-NMDA receptors in
the development and maintenance of the symptoms, as supported
by literature data [31].
c-fos Expression in the Neocortex and NMDA Antagonists
In vivo studies on the involvement of excitatory amino acid re-
ceptors in epileptiform discharges have indicated that NMDA re-
ceptors are active in the generation and maintenance of bursting
responses in the rat somatosensory cortex [28]. The distribution
of ionotropic glutamate receptors is uneven in the neocortex: in-
tracortical synapses of pyramidal neurons are mainly mediated by
NMDA receptors [54], whilst the thalamocortical input and the
corticothalamocortical neuronal network are rather associated with
AMPA receptors [23]. We consider that the significant decrease in
the number of Fos-immunopositive cells observed in the present
study is a consequence of a reduction in neuronal activity, probably
via blockade of the NMDA receptor-mediated neurotransmission
in the horizontal fibre plexus of the cortex and in other corticocor-
tical synapses [19]. On the other hand, the AMPA-mediated [23]
thalamocortical pathway remains active. This activity was most ap-
parent in the cases pretreated with ketamine and MK-801, in which
layer IV exhibited relatively high Fos immunoreactivity, indicating
the importance of non-NMDA-mediated stimulatory effects of tha-
lamocortical axons. The results obtained with amantadine indicated
that this drug was probably loosely bound in the NMDA channel,
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and it was removed by the intense cation fluxes during neuron hy-
peractivity [40]. The persistence of the motor seizure symptoms
following amantadine pretreatment supports this assumption.
c-fos Expression in the Hippocampus and NMDA Antagonists
Literature data lead us to assume that the limbic seizures pro-
duced by 4-AP are related to the enhancement of glutamatergic
transmission [35,44]. Antagonists of the NMDA receptor inhibit
seizure-induced c-fos mRNA expression in the dentate granule
cells [29], suggesting that dentate neuronal hyperactivity and
thereby c-fos induction are mediated by NMDA receptor activa-
tion. Furthermore, competitive and non-competitive NMDA recep-
tor antagonists prevented 4-AP seizure-induced neurodegeneration
in the CA1 and CA3 regions with an NMDA-mediated excito-
toxic mechanism [44]. However, both NMDA and non-NMDA
receptors play a role in the epileptiform discharges mediated by
the perforant path in the dentate gyrus [26]. Immunohistochemical
studies have confirmed the presence of AMPA receptor subunits in
the molecular layer of the dentate gyrus [38]. These observations
explain our finding that the non-competitive NMDA antagonists
exert a similar effect in all regions of the hippocampal formation,
in which they attenuate, but do not abolish, Fos protein immunos-
taining. Although the overall decrease in Fos protein-like staining
in the Ammon’s horn after pretreatment with NMDA antagonists
indicated the importance of NMDA-mediated glutamate action in
the maintenance of the seizure, the remaining Fos immunoreactiv-
ity highlighted the importance of non-NMDA glutamate receptors,
and probably other transmitter systems, in epileptogenesis.
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